BOSTON--(BUSINESS WIRE)--Renovia Inc. (“Renovia”), a company dedicated to discovering and delivering first-line digital therapeutic and diagnostic devices for women with pelvic floor disorders, today announced Tara Butler, M.D. has joined its Board of Directors.
Dr. Butler is a Managing Director at Ascension Ventures, which recently acted as a lead investor in Renovia’s Series B financing. Dr. Butler joined Ascension Ventures in 2002 after completing a residency in obstetrics and gynecology at Washington University in St. Louis. Prior to attending medical school, she held positions in business development at Medtronic, in finance at Honeywell, and as a laboratory research assistant at the University of Pennsylvania School of Medicine.
"We are thrilled to be able to partner with Tara and her colleagues at Ascension Ventures. Tara’s deep clinical background in women’s health, and her experience as a healthcare investor for the last 20 years across the medical device and diagnostics sectors, give her a unique perspective on the opportunities ahead as Renovia prepares to scale its business,” said Marc Beer, Co-Founder, Chairman and Chief Executive Officer of Renovia. “From the time of our first meeting with Tara, it has been clear that she and her colleagues are aligned with Renovia’s vision to provide new treatment options and improve patient outcomes.”
“Pelvic floor disorders such as urinary incontinence are incredibly common with enormous quality-of-life implications for millions of women. Unfortunately, there’s a tremendous need to improve treatment effectiveness due to delayed care-seeking and practical challenges in matching patients to the best therapeutic modality,” said Dr. Butler. “Renovia’s technology can capture data on a multitude of complex indicators of pelvic floor function and distill the data in a way that is both clinically actionable and intuitive to patients. I am thrilled to join a team focused on developing innovative approaches to treating this underserved patient population.”
Dr. Butler holds a BS in Economics and an MBA from the Wharton School of Business at the University of Pennsylvania, and a Doctor of Medicine from the University of Pennsylvania School of Medicine. She has been a board member or observer at various Ascension Ventures portfolio companies, including Apama Medical, Augmenix, Cardionomic, CHF Solutions, Confluent Surgical, CSA Medical, EBR Systems, EKOS Corporation, HemoSphere, Imperative Care, Instylla, Ivantis, MindFrame, Neurolutions, Ocular Therapeutix (NASDAQ: OCUL), Stereotaxis (NASDAQ: STXS), and TomoTherapy (NASDAQ: TOMO).
Renovia was formed to develop and commercialize products for better first-line diagnosis and treatment to improve the condition-specific quality of life for millions of women with pelvic floor disorders. Renovia's technology enables treatment via precise visualization of pelvic movement in real-time during pelvic floor muscle training, while monitoring usage and progress over time. As a women's health organization, Renovia is in pursuit of scalable and cost-effective care for pelvic floor disorders delivered through the power of digital health.
About Ascension Ventures
Ascension Ventures (www.ascensionventures.org) is a strategic healthcare investment firm with four funds and more than $800 million in capital under management. The firm was launched in 2001 by Ascension, the nation's largest Catholic and non-profit health system, and today invests on behalf of thirteen of the nation's leading community health systems. These health system limited partners collectively operate 474 hospitals, have 578,000 employees and generate $88 billion in annual revenue. AV collaborates with these partners to identify, invest in, and support strategically aligned private companies that are transforming the healthcare industry and enhancing the experience for patients, their families, and caregivers.